Overview

Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)

Status:
Active, not recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if axitinib can help to control kidney cancer. The safety of this drug will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Pfizer
Treatments:
Axitinib